AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Long-Term Blood Pressure Lowering for Secondary Stroke Prevention After Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis

By Prado Jose M

Background: Intracerebral hemorrhage (ICH) survivors face a 3-7% annual risk of recurrent stroke, and blood pressure (BP) remains the most modifiable determinant. Whether the absolute magnitude of benefit of long-term antihypertensive therapy differs between ICH subtypes — cerebral amyloid angiopathy (CAA, lobar) versus chronic hypertensive disease (deep) — has not been formally synthesized using subtype-specific baseline risks. Methods: We performed a systematic review and meta-analysis of randomized trials of long-term antihypertensive therapy (≥6 months) in adult ICH survivors. PubMed, Embase, and Cochrane CENTRAL were searched through May 2026. Hazard ratios (HRs) were pooled using random-effects (REML) models; prospective cohorts (Biffi 2015, Teo 2023) provided sensitivity triangulation. The pre-specified subtype-moderator analysis used PROGRESS-ICH RCT subgroup data (Arima 2010). Trial Sequential Analysis (TSA), risk-stratified number needed to treat (NNT) using literature-anchored baseline risks, and exploratory cost-analysis contextualized the findings. Certainty was appraised using GRADE. Results: Two randomized trials (TRIDENT, n=1,670; PROGRESS-ICH subgroup, n=719; total n=2,389) yielded a pooled HR for recurrent stroke of 0.56 (95% CI 0.42-0.77; p=0.0002; I ² =0%); information size reached 119% of the optimal target (TSA). Combined RCT and cohort analysis (n=5,362) confirmed the effect (HR 0.55; 95% CI 0.38-0.78; p=0.001), with no design-moderator difference (p=0.81). Subtype-stratified RCT estimates were directionally consistent: CAA/lobar HR 0.23 (95% CI 0.07-0.81) versus hypertensive/deep HR 0.54 (95% CI 0.31-0.96), with no statistically significant interaction (HR ratio 0.43; 95% CI 0.11-1.64; p=0.21). Applying the robust pooled HR (0.56) to literature-anchored 5-year baseline recurrence risks (CAA ~30%; hypertensive ~12%) yielded NNT ≈8 versus NNT ≈19 — a 2.5-fold larger absolute benefit in CAA-related ICH, driven by higher baseline risk. Exploratory cost-analysis using generic combination therapy suggested potential net savings across both subtypes. GRADE certainty for the primary outcome was MODERATE (downgraded for observational inclusion and imprecision). Conclusions: Long-term BP lowering after ICH approximately halves recurrent stroke risk across both ICH subtypes. The absolute benefit is approximately 2.5-fold greater in CAA-related ICH (NNT ≈8 versus ≈19 over 5 years), driven by higher baseline recurrence risk, supporting risk-stratified guideline reinforcement of structured BP control in all ICH survivors.

doi.org/10.1161/circ.154.suppl_1.18971Interventions

AgingResearch.News